236 related articles for article (PubMed ID: 19148480)
1. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer.
Di Vinci A; Sessa F; Casciano I; Banelli B; Franzi F; Brigati C; Allemanni G; Russo P; Dominioni L; Romani M
Int J Oncol; 2009 Feb; 34(2):449-56. PubMed ID: 19148480
[TBL] [Abstract][Full Text] [Related]
2. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
3. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
4. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
5. Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer.
Logotheti S; Michalopoulos I; Sideridou M; Daskalos A; Kossida S; Spandidos DA; Field JK; Vojtesek B; Liloglou T; Gorgoulis V; Zoumpourlis V
FEBS J; 2010 Jul; 277(14):3014-27. PubMed ID: 20528922
[TBL] [Abstract][Full Text] [Related]
6. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
7. Loss of p73 expression in six non-small cell lung cancer cell lines is associated with 5'CpG island methylation.
Liu K; Zhan M; Zheng P
Exp Mol Pathol; 2008 Feb; 84(1):59-63. PubMed ID: 18022156
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
9. Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer.
Daskalos A; Logotheti S; Markopoulou S; Xinarianos G; Gosney JR; Kastania AN; Zoumpourlis V; Field JK; Liloglou T
Cancer Lett; 2011 Jan; 300(1):79-86. PubMed ID: 20926182
[TBL] [Abstract][Full Text] [Related]
10. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.
Watson IR; Blanch A; Lin DC; Ohh M; Irwin MS
J Biol Chem; 2006 Nov; 281(45):34096-103. PubMed ID: 16980297
[TBL] [Abstract][Full Text] [Related]
11. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.
Yu J; Baron V; Mercola D; Mustelin T; Adamson ED
Cell Death Differ; 2007 Mar; 14(3):436-46. PubMed ID: 16990849
[TBL] [Abstract][Full Text] [Related]
12. Impact of WWOX alterations on p73, ΔNp73, p53, cell proliferation and DNA ploidy in salivary gland neoplasms.
Gomes CC; Diniz MG; Oliveira CS; Tavassoli M; Odell EW; Gomez RS; De Marco L
Oral Dis; 2011 Sep; 17(6):564-71. PubMed ID: 21332605
[TBL] [Abstract][Full Text] [Related]
13. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
[TBL] [Abstract][Full Text] [Related]
14. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
15. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.
Becker K; Pancoska P; Concin N; Vanden Heuvel K; Slade N; Fischer M; Chalas E; Moll UM
Int J Oncol; 2006 Oct; 29(4):889-902. PubMed ID: 16964385
[TBL] [Abstract][Full Text] [Related]
16. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.
Simões-Wüst AP; Sigrist B; Belyanskaya L; Hopkins Donaldson S; Stahel RA; Zangemeister-Wittke U
J Neurooncol; 2005 Mar; 72(1):29-34. PubMed ID: 15803372
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
Guan M; Chen Y
J Clin Pathol; 2005 Nov; 58(11):1175-9. PubMed ID: 16254107
[TBL] [Abstract][Full Text] [Related]
18. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
Jung YS; Qian Y; Chen X
J Biol Chem; 2011 Oct; 286(41):35388-35395. PubMed ID: 21852228
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS
J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112
[TBL] [Abstract][Full Text] [Related]
20. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
Emmrich S; Wang W; John K; Li W; Pützer BM
Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
